AnaptysBio Statistics
Share Statistics
AnaptysBio has 30.43M shares outstanding. The number of shares has increased by 13.7% in one year.
| Shares Outstanding | 30.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.76% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 25.95M |
| Failed to Deliver (FTD) Shares | 6.23K |
| FTD / Avg. Volume | 0.99% |
Short Selling Information
The latest short interest is 6.99M, so 22.96% of the outstanding shares have been sold short.
| Short Interest | 6.99M |
| Short % of Shares Out | 22.96% |
| Short % of Float | 26.86% |
| Short Ratio (days to cover) | 10.21 |
Valuation Ratios
The PE ratio is -3.52 and the forward PE ratio is -3.35.
| PE Ratio | -3.52 |
| Forward PE | -3.35 |
| PS Ratio | 33.61 |
| Forward PS | 10 |
| PB Ratio | 6.55 |
| P/FCF Ratio | -4.74 |
| PEG Ratio | n/a |
Enterprise Valuation
AnaptysBio Inc. has an Enterprise Value (EV) of 558.56M.
| EV / Earnings | -3.41 |
| EV / Sales | 32.56 |
| EV / EBITDA | -3.9 |
| EV / EBIT | -3.4 |
| EV / FCF | -4.59 |
Financial Position
The company has a current ratio of 10.87, with a Debt / Equity ratio of 0.2.
| Current Ratio | 10.87 |
| Quick Ratio | 10.87 |
| Debt / Equity | 0.2 |
| Total Debt / Capitalization | 16.82 |
| Cash Flow / Debt | -6.78 |
| Interest Coverage | -9.09 |
Financial Efficiency
Return on equity (ROE) is -1.86% and return on capital (ROIC) is -155.22%.
| Return on Equity (ROE) | -1.86% |
| Return on Assets (ROA) | -0.36% |
| Return on Capital (ROIC) | -155.22% |
| Revenue Per Employee | 146.64K |
| Profits Per Employee | -1.40M |
| Employee Count | 117 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -4.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -32.91% in the last 52 weeks. The beta is -0.24, so AnaptysBio 's price volatility has been lower than the market average.
| Beta | -0.24 |
| 52-Week Price Change | -32.91% |
| 50-Day Moving Average | 18.8 |
| 200-Day Moving Average | 26.71 |
| Relative Strength Index (RSI) | 41.73 |
| Average Volume (20 Days) | 629.67K |
Income Statement
In the last 12 months, AnaptysBio had revenue of 17.16M and earned -163.62M in profits. Earnings per share was -6.08.
| Revenue | 17.16M |
| Gross Profit | 14.78M |
| Operating Income | -164.41M |
| Net Income | -163.62M |
| EBITDA | -143.16M |
| EBIT | -164.41M |
| Earnings Per Share (EPS) | -6.08 |
Balance Sheet
The company has 35.97M in cash and 17.81M in debt, giving a net cash position of 18.15M.
| Cash & Cash Equivalents | 35.97M |
| Total Debt | 17.81M |
| Net Cash | 18.15M |
| Retained Earnings | -614.10M |
| Total Assets | 493.42M |
| Working Capital | 404.80M |
Cash Flow
In the last 12 months, operating cash flow was -120.80M and capital expenditures -807.00K, giving a free cash flow of -121.61M.
| Operating Cash Flow | -120.80M |
| Capital Expenditures | -807.00K |
| Free Cash Flow | -121.61M |
| FCF Per Share | -4.52 |
Margins
Gross margin is 86.15%, with operating and profit margins of -958.27% and -953.66%.
| Gross Margin | 86.15% |
| Operating Margin | -958.27% |
| Pretax Margin | -953.68% |
| Profit Margin | -953.66% |
| EBITDA Margin | -834.43% |
| EBIT Margin | -958.27% |
| FCF Margin | -708.79% |
Dividends & Yields
ANAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -40.7% |
| FCF Yield | -26.75% |
Analyst Forecast
The average price target for ANAB is $38, which is 154.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $38 |
| Price Target Difference | 154.4% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | -1.17 |
| Piotroski F-Score | 3 |